|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Analysis of survival with modified docetaxel,cisplatin,fluorouracil(mDCF),and bevacizumab(BEV)in patients with metastatic gastroesophageal(GE)adenocarcinoma:results of a phase II clinical trial显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | J Clin Oncol2009，，： | 1 |
| 2 | Analysis of survival with modified docetaxel,cisplatin,fluorouracil(mDCF),and bevacizumab(BEV) in patients with metastatic gastroesophageal(GE)adenocarcinoma:Results of a phase Ⅱ clinical trial显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | ASCO Meeting2009，27，： | 1 |
| 3 | PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab显示文摘 | Jhawer M Goel S Wilson A J | 2008 | Cancer Res2008，68，6： | 1 |
| 4 | PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab 显示文摘 | Jhawer M Goel S Wilson AJ | 2008 | Cancer Res2008，68，6： | 1 |
| 5 | Phase Ⅱ study of modified docetaxel,cisplatin,and fluorouracil with beva- cizumab in patients with metastatic gastroesophageal ade- nocarcinoma显示文摘 | Shah MA Jhawer M Ilson DH | 2011 | J Clin Oncol2011，29，7： | 1 |
| 6 | PIK3CA mutation/PTEN expres- sion status predicts response of colon cancer ceUs to the epidermal growth factor receptor inhibitor cetuximab 显示文摘 | Jhawer M Goel S Wilson AJ | 2008 | Cancer Res2008，68，6： | 1 |
| 7 | Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase I1 clinical trial显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | J Clin Oncol2009，27，15： | 1 |
| 8 | PhaseⅡstudy of modified docetaxel,cisplatin,and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma显示文摘 | Shah MA Jhawer M llson DH | 2011 | J Clin Oncol2011，29，7： | 1 |
| 9 | PIK3CA mutation/ PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab显示文摘 | Jhawer M Goel S Wilson AJ | 2008 | Cancer Res2008，68，： | 1 |
| 10 | Phase Ⅱ trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma显示文摘 | JHAWER M ROSEN L DANCEY J | 2007 | Invest New Drugs2007，25，2： | 1 |
| 11 | Analysis of survival with modified docetaxel, cisplatin, flnorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase lI clinical trial显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | J ClinOncol2009，27，： | 1 |
| 12 | PIK3CA mutation/PTEN ex- pression status predicts response of colon cancer ceils to the epider- mal growth factor receptor inhibitor cetuximab 显示文摘 | Jhawer M Goel S Wilson AJ | 2008 | Cancer Res2008，68，6： | 1 |
| 13 | Analysis of survival with modified docetaxel, eisplatin, fluorouraeil (mDCF) , and bevaeizumab (BEV)in patients with metastatic gas Uroesophageal (GE) adenocarcinoma: results of a phase1I clinical trial 显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | Clin Oneo12009，27，15： | 1 |
| 14 | Analysis of survival with modified docetaxel, cisplatin, fluoreuracil ( mDCF), and bevacizumab ( BEV ) in patients with metastatic gastroesophageal ( GE ) adeneearcinoma: Results of a phase II clinical trial显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | ASCO Meeting2009，27，： | 1 |
| 15 | Analysis of survival with modi-fied docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab(BEV) in patients with metastatic gastroesophageal (GE) adenocarci-noma: Results of a phase II clinical trial(M)显示文摘 | Kelsen D Jhawer M Ilson D | 2009 | J Clin Oncol (MeetingAbstracts)2009，，： | 1 |
| 16 | PIK3CA mutation/ PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor eetuximab 显示文摘 | Jhawer M Goel S Wilson AJ | 2008 | Cancer Res2008，68，6： | 1 |
| 17 | Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer:gene expression analysis with pathologic validation显示文摘 | Jhawer M Ciot D Brennan M | 2009 | Am J Clin Oncol2009，32，4： | 1 |
| 18 | Pik3ca mutation/Pten expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab 显示文摘 | Jhawer M Goel S Wilson AJ | 2008 | Cancer Res2008，68，6： | 1 |
| 19 | Phase 11 study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma 显示文摘 | Shah MA Jhawer M Ilson DH | 2011 | J Clin On- col2011，29，7： | 1 |
| 20 | Phase II study of modified docetaxel, cispla- tin, and fluorouracil with bevacizumah in patients with metastatic gastroesophageal adenocarcinoma 显示文摘 | Shah MA Jhawer M | 2011 | J Clin Oncol2011，29，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员